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In the United States alone, 400,000 people suffer from Multiple Sclerosis(MS), a disease in 
which the immune system attacks neurons in the central and peripheral nervous systems (CNS, 
PNS). Currently, no cure exists, and treatment methods often only mildly alleviate symptoms. 
Therefore, current researchers are finding new methods to treat the disease, specifically the role 
that tolerized dendritic cells (DCs) combined with varying biomaterials and cytokine delivery 
mechanisms play when exposed to an in vitro murine model. The research performed in this 
paper examined the morphology and the viability of adherent vs non-adherent DCs encapsulated 
in PEG4MAL hydrogel with varying weight percentages of the polymer.  Confocal microscopy 
and flow cytometry were used to analyze cell viability. Moreover, tolerization of DCs with 
interleukin-10 (IL-10) was examined and the most promising method for cytokine delivery to 
DCs in a PEG hydrogel was investigated. It was found that adherent DC’s have highest viability 
in lower weight percent PEG4MAL hydrogels compared to non-adherent DC’s and that 
PEGylated IL-10 is the most efficient mechanism to introduce the cytokine to the DCs. 
Analyzing the thiolation of IL-10 was then the first step of this process, and results are 
underway. Future studies will optimize the characteristics of the hydrogel to allow for the 
greatest DC phenotype and viability. In turn, this can lead to an in vivo model and offer a more 






It is estimated that 400,000 people suffer from MS in the United States while 2.5 million patients 
endure the disease worldwide.1 MS is defined as an autoimmune disease in which the immune 
system attacks the CNS, specifically the myelin sheath, a fatty compound that protects the axon 
of nerve cells.1 Not only does this decrease the speed in which signals travel through nerve 
endings, but it causes inflammation and scarring of the nerve tissue, a process which creates 
plaques.1 Neurons are found throughout the entire body, so the entirety of the pathophysiology 
and the mechanism for the deterioration of myelin in different locations (CNS and PNS) is 
unknown. However, experts in immunology and neurology have suggested that one of the first 
locations of the lesions occurs in the BBB, which prevents certain substances from entering the 
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brain and spinal tissue of the CNS.1 A mechanism for this demyelination process begins with the 
activation of myelin-reactive T-cells by antigen presenting cells, microglia, macrophages, or B 
cells (Figure 1). The T-cells produce adhesion molecules that allow for entry through the BBB. 
Once in the CNS, T-cells can produce a variety of pro-inflammatory molecules that promotes 
increase in both inflammation and the recruitment of various other inflammatory promoting 
cells. Moreover, free radicals and toxins, usually released to protect the body in an immune 
response, can cause further damage to the myelin sheath.2 In light of this information, MS is 
considered to be a T-cell mediated disease; the activation of these destructive T-cells, however, 
are still widely studied.3 One of the most commonly investigated antigen-presenting cells that 
dictates a majority of the scope of T-cell activation and participation in MS is the tolerized DC, 
which can suppress an immunological response by activating T-regulatory cells (see Dendritic 
cells and MS). 
 
 
Figure 1: Image representing the potential mechanism of demyelination. There are various antigen-presenting cells (APCs); 










Symptoms and Diagnosis 
 
Because neurons and nerve tissues have varying functions, different symptoms can be 
experienced. For example, affected neurons associated with the vestibular system can cause 
dizziness while inflamed sensory or spinal neurons can cause chronic pain and tingling in 60% of 
patients (Figure 2). Lesions, scarring, and inflammation can occur in various areas of the body. 
Other common symptoms include double vision, fatigue, slurred speech, difficulty walking, and 
even depression.4 
Figure 2: Representation of a symptom of pain and tingling experienced by a patient suffering from lesions in the lumbar and 
sacral nerves of the spinal cord.3 
 
For some, symptoms are mild and manageable; however, for many, loss of bladder 
function and muscle tone cause serious complications and significantly decrease quality of life. 
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Therefore, proper diagnosis is often vital. Early diagnosis is rare due to the fact that the disease is 
not hereditary, as it is developed in patients over time. In order to properly diagnose MS, 
clinicians must use MRI technology and CSF analysis to find neuronal damage in two different 
areas of the body and provide evidence that the damage occurred different occasions.5 After 
diagnosis, a treatment regimen is discussed, as there is no cure for the disease. Various 
treatments include therapies and drugs that modify and delay disease progression. Patients often 
alter medications due to ineffectiveness; therefore, novel forms of treatment and therapies are 
being widely studied to improve upon what exists on the market today.6 
 
Dendritic Cells and MS 
 
Common APCs found in the body and affect T-cell activation and function are known as 
DC’s. DC’s are known to boost primary immune function and induce immunological tolerance.7 
They link the innate and adaptive immune system by ingesting antigens and presenting potential 
harmful bacteria to T-cells via the cell surface.8 Normal functioning DC’s are vital to the proper 
functioning of the immune system, for they can activate, shape, and even prevent the harmful 
immune responses found in diseases such as MS.7 However, studies have shown that patients 
with MS have abnormally functional DC’s in their CSF.9 These abnormalities are caused by 
miniscule changes in genetic information which can significantly compromise the body’s ability 
to carry out an immune response and, according to recent findings, cause an 
immunoinflammatory response as found in MS.10 A study by the International Multiple Sclerosis 
Genetic Consortium showed that genetic mutations can predispose patients to MS due to 
polymorphism while a study by Tailer et al. identified genetic mutations as a cause in the 
absence of certain subsets of DC’s that are responsible for immunoregulation and producing 
interferons and cytokines that are used in current MS therapies.11,12 Though aberrant DC’s have 
shown to positively correlate with the progression of the disease, normal functioning DC’s have 
shown to embody therapeutic properties as they can be tolerized to effect T-regulator cells to halt 
an immune response. Yogev et al. found that the extinction of DC’s in the murine model of MS, 
known as EAE, was related to the advancement of the disease. Therefore, in order to find a more 
efficient therapy for the treatment of MS, we have turned to studying various methods of 
maintaining various DC viability (adherent vs. non-adherent) on various platforms. 
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Biomaterials and Dendritic Cells 
 
A specific example of a platform utilized to investigate the viability and function of DC’s is the 
in vitro manipulation and engineering of biomaterials as a platform for cell maturation and 
cytokine delivery (Figure 3). 
Figure 3: Descriptive image highlighting the use of biomaterials to allow for immature DC (iDC) maturation or tolerization. 
Eventually, allowing for antibody production and potential MS treatment.14 
 
This is due to the fact that biomaterials, when designed with a compatibility specific to the cell, 
have shown to be agonists of maturation and an increased life span of the cell.14 Cell 
compatibility of the material can be engineered by the manipulation of mechanical properties, 
weight percentage (wt%) of components, and varying cytokine and drug delivery mechanisms 
(see Direct Conjugation and Microgel Delivery).  A common and extremely important cytokine 
delivered to DC’s is interleukin-10 (IL-10).15 IL-10 transforms the iDC’s into tDC’s which can 
then differentiate into T helper cells 1 and 2.16,17,18 These cells allow for the secretion of 
antibodies from B cells as well as activate T regulatory cells to kill infected cells as seen with 
MS. Therefore, the successful delivery of IL-10 to iDC’s on a properly chosen biomaterial 
platform is an extremely promising approach to a novel treatment for MS. 
Depending on the strategy, biomaterials can induce maturation of cells or control it. In order to 
allow for the incorporation of cytokines such as IL-10, it is important to choose a biomaterial 
that suppresses the maturation of the iDCs so that it can be controlled. Materials such as PLGA 
and chitosan have induced maturation prematurely.19 Experts at the Georgia Institute of 
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Technology have carried out experiments involving poly-ethylene glycol (PEG) hydrogels as a 
biomaterial suitable for seeding cells and incorporating various proteins.19,20 For example, Phelps 
et al. found that a PEG hydrogel seeded with human umbilical vein endothelial cells and 
angiogenic factors (quantified by ELISA) and delivered in situ in the small bowel mesentery of 
diabetic mice significantly improved the islet-islet engraftment and vascularization as well as 
increased weight gain in the mice.20 Moreover, Hume et al. found increased bioactivity and 
tolerized signals when seeding DC’s in a PEG hydrogel and incorporating cytokines and 
secondary signals.19 Therefore the biomaterial investigated in this study is a PEG-4MAL 
hydrogel with varying weight percent to analyze DC viability and activation. 
 
Direct Conjugation vs. Microgel Delivery 
 
Concurrent with hydrogel analysis is the analysis of incorporating IL-10 to DCs, as they induce 
tolerization. There are two main approaches to deliver IL-10 to DCs. Direct conjugation of IL-10 
to the hydrogel (PEGylated IL-10) has shown that IL-10 has the ability to be thiolated as well as 
has an increased clinically relevant bioactivity. Meanwhile, loaded microgel delivery has a 
highly tunable release of IL-10. Direct conjugation can affect a functional network of DC’s 
seeded onto a PEG hydrogel while the microgels have the potential to have issues with 
reproducibility of synthesis. We have analyzed both approaches in the Babensee lab. This 
research determined which delivery method of IL-10 allows for highest bioactivity through 
various experiments implemented in parallel (see Conjugation vs Microgel Decision Matrix 
Generation) and fine-tuning the hydrogel properties in order to allow for optimized dendritic cell 
tolerization and maturation. Both methods were analyzed using a flow chart and researching 
feasibility; however, the decision to move forward with PEGylated IL-10 instead of completing 
both experiments in parallel was made. The first experiment to confirm that direct conjugation is 
the correct method to deliver IL10 was the thiolation of IL-10 using Traut’s Reagent. 
Verification of this thiolation was performed using a BCA Assay and Ellman’s reagent almost 











The research highlighted in this document was led by Nicholas Beskid and assisted by Naomi 
Wildschut. It examined the effect of varying weight percentages of PEG on adherent vs. non-
adherent cells with iDC, mDC, and tDC controls. This is to determine which type of cell to 
utilize in further studies as well as analyze weight percentage of PEG. After cell culture and 
passaging, the iDC’s were encapsulated in 20kDa PEG-4Mal hydrogels that were VPM 
crosslinked with 1mM RGD functionalization. The various weight percentages tested were 3.5%, 
4.5%, 6%, and 10 %. Confocal microscopy and flow cytometry were utilized in order to analyze 
cell morphology and viability. It was deemed that lower weight percentage of PEG and 
utilization of adherent cells provided the highest viability as seen through the confocal 
microscope. Moreover, the testing of two IL-10 delivery approaches to iDCs were discussed in 
the Babensee lab. Analysis of DC activity when tolerized, formation of experimental plan, and 
thiolation of the IL-10 for the direct conjugation were completed and are detailed below. The 




Dendritic Cell Culture 
 
On Day 0, tubes were prepared with 100mL HBSS and 5% FBS. Four mice were sacrificed using 
proper sealed CO2 containers, two at a time, for ten minutes each (proper and humane IACUC 
protocols were followed). Using forceps and tweezers, the skin was removed, the leg was clipped 
above the hip, and the muscles were disposed before placing the leg bone in a 50mL tube with 
HBSS and 5% FBS (goal is an intact femur and tibia to preserve cell viability). New tubes were 
used for each mouse to avoid cross contamination. 
In aseptic environment, the ends of the bone were cut and flushed with HBS and 10% 
FBS. Cell clumps were broken up using the back of a plunger and washed with HBS; they were 
centrifuged for 10 minutes and 5 minutes respectively. Cells were counted using a multisizer 
(size>5um), suspended in media, and 3 ml of solution was added to each well in a labeled 24 
well plate (mDC, tDC, iDC). Cells were supplemented with cytokines and swirled manually 
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clockwise and anti-clockwise. After this process, the overall expected outcome must yield more 
than 50e6 cells from the bone marrow isolation. 
Media components : 429.5mL DMEM (Cellgro: 10-017-CV), 5mL pen/strep (Cellgro 
30.002-Cl),5mL NE Amino Acids (Cellgro, 25-025-Cl),5mL Na Pyruvate (Cellgro, 25-000-Cl), 
5mL HEPES (Cellgro, 25-060-Cl),0.5 2-mercaptoethanol (Gibco, 21985-023),50mL FBS heat 
inactivated (Gibco: 16000-044) 
 
General Dendritic Cell Passaging 
 
On days 2,4, and 6, well plates were swirled manually 10 times clockwise and counterclockwise. 
Half of the cell culture media was removed (18ml per mouse) and placed in 50ml centrifuge 
tube/centrifuged for 5 minutes (300XG/1200rpm). Cell media was removed from the centrifuge 
tubes and new media was added to the tubes. A pellet of cells on the bottom of the tube could be 
observed. The DC’s were re-added to the wells. On day 6, various cytokines were added (20ng 
IL-4, 20ng GM-CSF per 1,000,000 cells) and swirled.  To obtain mDC’s, place 1 microgram (per 
1,000,000 cells) of Lipopolysaccharide to the well. To obtain tDCs place 50ng of interleukin-10 
to the well. Lastly, iDC’s received no treatment. Moreover, non-adherent and adherent iDC’s 
were encapsulated in VPM crosslinked gels of weight percents 3.5%, 4.5%, 6% and 10%. 
` 
Phenotype and Viability Analysis 
 
On day 7, brightfield microscopy, confocal microscopy and flow cytometry (FORTESSA) were 
used to analyze the physical and chemical characteristics of the adherent vs non-adherent cells 
with varying weight percentages. 
 
Conjugation vs Microgel Decision Matrix Generation 
 
An experimental plan was created in order to compare approaches of direct conjugation vs. 
loaded microgel delivery of IL-10 (Flow Chart 1). 
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Flow Chart 1. Experimental if/then statements detailing informed decision making process for IL10 delivery approach 
 
Thiolation of IL-10 
 
Thiolation of IL-10 was performed using Traut’s Reagent and verified via Ellmann’s reagent. IL-
10 at a concentration of no lower than 0.1mg/ml was to be thiolated in PBS with an adjusted pH 
of 8. 5mM EDTA was added to the buffer and protein solution to prevent oxidation. Traut’s 
stock was made at 2mg/ml and initially diluted in H2O. 30-fold excess of Traut’s solution was 
added to protein in solution and incubated with gentle shaking. Spin columns then separated the 
thiolated protein. 
The verification of thiolation using Ellman’s reagent began by preparing a set of cysteine 
standards by dissolving Cysteine Hydrochloride Monohydrate at the following concentrations in 




Table 1. Amounts of Cysteine needed to create standard solutions with reaction buffer. 
 
 
50 uL of Ellman’s reagent was added to a mixture of 2.5mg/ml reaction buffer and 250uL of 
each standard solution (Table 1) to different test tubes. They were incubated for 15 minutes, 
placed in a plate reader, and varying absorbance were read at 412 nm. 
 
Results 
Phenotype and Viability 
On Day 7, brightfield microscopic images were taken of the adherent and non-adherent cells to 
establish variance in morphology with each PEG weight percent. Figures 4 and 5 shows the 
sparse and elongated morphology of adherent and non-adherent cells with higher weight percent 
of PEG. 










Figure 4. Brightfield microscopy images of the adherent cells encapsulated in PEG-4MAL hydrogel with varying weight 
percentages. It is shown that higher weight percent has sparse cells and elongated morphology when compared to lower weight 















Figure 5. Brightfield microscopy images of the non-adherent cells encapsulated in PEG-4MAL hydrogel with varying weight 
percentages. It is shown that higher weight percent has sparce cells and elongated morphology when compared to lower weight 
percent of PEG, similar to the adherent cells. 
 
Confocal microscopy was used to analyze the viability of the adherent and non-adherent cells in 
using calcien AM (4uM) and EthD-1 (4uM) in Figures 6 and 7. Additional analysis was 
performed to compare the adherent cells to the non-adherent cells after the confocal microscopy 
was performed 
3.5%    4.5%   6%   10% 
Figure 6. Confocal images of adherent cells at varying weight percentages of PEG-4MAL. The viability (green due to calcian 
AM, red due to EthD-1) of the cells in lower weight percentages is significantly higher than those in lower weight percentages. 
The top row is 4x and the bottom row is 20x zoom. 
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3.5%    4.5%   6%   10% 
Figure 7. Confocal images of non-adherent cells at varying weight percentages of PEG-4MAL. The viability (green due to 
calcian AM, red due to EthD-1) of the cells in lower weight percentages is significantly higher than those in lower weight 
percentages. The top row is 4x and the bottom row is 20x zoom. 
 
In order to confirm the results found using brightfield and confocal microscopy, flow cytometry 
was performed. Figure 8 shows higher percentage viability in adherent cells encapsulated in low 
















Figure 8 Graph of viability of adherent cells vs non-adherent cells from flow cytometry. The graph shows higher percentage 






































PEGylated IL-10 vs. Microgel Delivery 
 
After analysis of the flow chart and discussion with the primary investigator, Dr. Julia Babensee, 
it was deemed that extensive experimentation to determine the best manner to introduce IL-10 to 
DC’s was unnecessary. Due to the higher feasibility of PEGylated IL-10 as opposed to the 
microgel IL-10 delivery mechanism, the PEGylated IL-10 was chosen. The results for the first 
step in this process are set to be achieved on 01 May 2018. 
 
Discussion and Conclusion 
The differential effects PEG hydrogel on viability and functional changes of DC phenotypes 
were observed in the present study. Given the results of the study and extra analysis shown in 
Figure 9, it is shown that adherent DCs encapsulated in PEG-4MAL hydrogel with lower weight 
percent produce the higher viability and lower activation when compared to non-adherent DCs 















Figure 9. Images show the adherent cells had better viability than non-adherent cells in the same gel formulation. On the left, the 
images shown are taken from adherent and non-adherent at 3.5%. Moreover, the higher weight percentage for PEG was 
detrimental to cell viability. On the right, the images were taken from adherent cells at 6% and 10% 
 
The higher viability in the adherent cell group is important to keep into consideration when 
moving forward with experimentations wherein other manipulations of the hydrogel can further 
optimize concentration and viability. The increased viability of adherent cells could be due to the 




it has been shown that adherent cells are purer than non-adherent cells.21 This data is significant 
because future work in the lab involving the manipulation of hydrogels (mechanical properties, 
cytokine delivery) will involve adherent dendritic cells to optimize viability, phenotype, and 
concentration. Moreover, we can now look at decreasing the weight percent to 2-3% in order to 
further examine the effect of the hydrogel on dendritic cell viability.  
 
The overall goal is to have an optimized platform for tolerized dendritic cells. To do this, IL-10 
needed to be incorporated in the model. The chosen direction was to directly conjugate the IL-10 
and then encapsulate the dendritic cells with the PEGylated IL-10 because of the time and 
resources of the lab. A previous lab assistant successfully thiolated human IL-10 and a parallel 
was drawn to murine IL-10. Therefore, the decision to pursue direction conjugation was made 
and the ability to thiolate of murine IL-10 needed to be verified. Simply put, if sulfylhydrate 
groups are added on to the IL-10 structure, it can be crosslinked with the PEG to form a network 
that can then be encapsulated by dendritic cells and further analyzed. The results of this 
experiment are pending; however, if successful, the next steps include analysis of the IL-10 
within the PEG network. Questions to be answered would include: 
1. Does the PEG negatively affect the bio activity of the IL-10? 
2. Does the IL-10 negatively affect the mechanical properties of the PEG hydrogel? 
Future studies will continue the manipulation of the PEG-4MAL hydrogel in order to optimize 
dendritic cell phenotype and viability. This includes changes in mechanical properties to be 
tailored to conditions best suited for adherent dendritic cells. Similarly, if thiolation of IL-10 
proves to be completely unsuccessful, it would be possible to pursue a microgel delivery 
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